Clavulanate lithium | CAS#61177-44-4 | β-lactamase inhibitor

MedKoo Cat#: 317538 | Name: Clavulanate lithium

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Clavulanic is a β-lactam drug that functions as a mechanism-based β-lactamase inhibitor. While not effective by itself as an antibiotic, when combined with penicillin-group antibiotics, it can overcome antibiotic resistance in bacteria that secrete β-lactamase, which otherwise inactivates most penicillins. In its most common preparations, potassium clavulanate (clavulanic acid as a salt of potassium) is combined with: Amoxicillin-clavulanic acid is a first-line treatment for many types of infections, including sinus infections, and urinary tract infections, including pyelonephritis.

Chemical Structure

Clavulanate lithium

CAS#61177-44-4 (lithum)

Theoretical Analysis

MedKoo Cat#: 317538

Name: Clavulanate lithium

CAS#: 61177-44-4 (lithum)

Chemical Formula: C8H8LiNO5

Exact Mass: 0.0000

Molecular Weight: 205.09

Elemental Analysis: C, 46.85; H, 3.93; Li, 3.38; N, 6.83; O, 39.00

Price and Availability

Size	Price	Availability	Quantity
200mg	USD 1,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

57943-81-4 (sodium) 61177-44-4 (lithum) 58001-44-8 (free acid) 61177-45-5 (potassium)

Synonym

Clavulanate Lithium; Clavulanate; MM 14151; MM-14151; MM14151;

IUPAC/Chemical Name

(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate lithium

InChi Key

JMRXTGCDVQLAFM-JSYANWSFSA-M

InChi Code

InChI=1S/C8H9NO5.Li/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4;/h1,6-7,10H,2-3H2,(H,12,13);/q;+1/p-1/b4-1-;/t6-,7-;/m1./s1

SMILES Code

O=C([C@@H](/C(O[C@]1([H])C2)=C/CO)N1C2=O)[O-].[Li+]

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 205.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Abdel-Aziz MI, Ali MA, Hassan AK, Elfaham TH. Warfarin-drug interactions: An emphasis on influence of polypharmacy and high doses of amoxicillin/clavulanate. J Clin Pharmacol. 2016 Jan;56(1):39-46. doi: 10.1002/jcph.583. Epub 2015 Sep 29. PubMed PMID: 26138877. 2: Ferrer P, Amelio J, Ballarín E, Sabaté M, Vidal X, Rottenkolber M, Schmiedl S, Laporte JR, Ibáñez L; PROTECT Work Package 2.. Systematic Review and Meta-Analysis: Macrolides and Amoxicillin/Clavulanate-induced Acute Liver Injury. Basic Clin Pharmacol Toxicol. 2015 Dec 26. doi: 10.1111/bcpt.12550. [Epub ahead of print] PubMed PMID: 26707367. 3: Wan KS, Wu WF, Chen TC, Wu CS, Hung CW, Chang YS. Comparison of amoxicillin + clavulanate with or without intranasal fluticasone for the treatment of uncomplicated acute rhinosinusitis in children. Minerva Pediatr. 2015 Dec;67(6):489-94. PubMed PMID: 26530491. 4: Sutherland CA, Crandon JL, Nicolau DP. Defining Extended Spectrum β-Lactamases: Implications of Minimum Inhibitory Concentration-Based Screening Versus Clavulanate Confirmation Testing. Infect Dis Ther. 2015 Oct 20. [Epub ahead of print] PubMed PMID: 26481506; PubMed Central PMCID: PMC4675766. 5: Rossi B, Soubirou JF, Chau F, Massias L, Dion S, Lepeule R, Fantin B, Lefort A. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection. Antimicrob Agents Chemother. 2015 Nov 2;60(1):424-30. doi: 10.1128/AAC.02018-15. PubMed PMID: 26525800. 6: Soroka D, Li de la Sierra-Gallay I, Dubée V, Triboulet S, van Tilbeurgh H, Compain F, Ballell L, Barros D, Mainardi JL, Hugonnet JE, Arthur M. Hydrolysis of clavulanate by Mycobacterium tuberculosis β-lactamase BlaC harboring a canonical SDN motif. Antimicrob Agents Chemother. 2015 Sep;59(9):5714-20. doi: 10.1128/AAC.00598-15. Epub 2015 Jul 6. PubMed PMID: 26149997; PubMed Central PMCID: PMC4538473. 7: Goodwani S, Rao PS, Bell RL, Sari Y. Amoxicillin and amoxicillin/clavulanate reduce ethanol intake and increase GLT-1 expression as well as AKT phosphorylation in mesocorticolimbic regions. Brain Res. 2015 Oct 5;1622:397-408. doi: 10.1016/j.brainres.2015.07.008. Epub 2015 Jul 10. PubMed PMID: 26168897; PubMed Central PMCID: PMC4562883. 8: Palmero D, González Montaner P, Cufré M, García A, Vescovo M, Poggi S. First series of patients with XDR and pre-XDR TB treated with regimens that included meropenen-clavulanate in Argentina. Arch Bronconeumol. 2015 Oct;51(10):e49-52. doi: 10.1016/j.arbres.2015.03.012. Epub 2015 May 27. English, Spanish. PubMed PMID: 26026689. 9: Pagliotto AD, Caleffi-Ferracioli KR, Lopes MA, Baldin VP, Leite CQ, Pavan FR, Scodro RB, Siqueira VL, Cardoso RF. Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination. J Microbiol Immunol Infect. 2015 Sep 21. pii: S1684-1182(15)00849-X. doi: 10.1016/j.jmii.2015.08.025. [Epub ahead of print] PubMed PMID: 26454420. 10: Kim SH, Saide K, Farrell J, Faulkner L, Tailor A, Ogese M, Daly AK, Pirmohamed M, Park BK, Naisbitt DJ. Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury. Hepatology. 2015 Sep;62(3):887-99. doi: 10.1002/hep.27912. Epub 2015 Jul 23. PubMed PMID: 25998949. 11: Álvarez Otero J, González González L, Enríquez Gómez H, de la Fuente Aguado J. [Cholestatic hepatitis caused by amoxicillin-clavulanate of torpid evolution]. Enferm Infecc Microbiol Clin. 2015 Jul 8. pii: S0213-005X(15)00250-5. doi: 10.1016/j.eimc.2015.06.004. [Epub ahead of print] Spanish. PubMed PMID: 26164264. 12: Martín-Barrasa JL, Méndez Cordovez C, Espinosa de los Monteros y Zayas A, Juste de Santa Ana MC, Clavo Varas B, Herráez Thomas P, Bordes Benitez A, Montoya-Alonso JA, García-Bello M, Artiles Campelo F, Tejedor-Junco MT. Rectal pre-treatment with ozonized oxygen (O3) aggravates clinic status in septic rats treated with amoxicillin/clavulanate. Enferm Infecc Microbiol Clin. 2015 Aug-Sep;33(7):469-75. doi: 10.1016/j.eimc.2014.09.006. Epub 2014 Nov 4. PubMed PMID: 25459192. 13: Egesborg P, Carlettini H, Volpato JP, Doucet N. Combinatorial active-site variants confer sustained clavulanate resistance in BlaC β-lactamase from Mycobacterium tuberculosis. Protein Sci. 2015 Apr;24(4):534-44. doi: 10.1002/pro.2617. Epub 2014 Dec 30. PubMed PMID: 25492589; PubMed Central PMCID: PMC4380984. 14: Cielecka-Piontek J, Paczkowska M, Zalewski P, Lewandowska K, Barszcz B. Solid-state stability and compatibility studies of clavulanate potassium. Pharm Dev Technol. 2015 Mar;20(2):146-52. doi: 10.3109/10837450.2013.852571. Epub 2013 Nov 13. PubMed PMID: 24219797. 15: Ferrer P, Sabaté M, Ballarín E, Fortuny J, Rottenkolber M, Schmiedl S, Laporte JR, Ibáñez L. Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007-2010. Springerplus. 2015 Oct 15;4:612. doi: 10.1186/s40064-015-1398-4. eCollection 2015. PubMed PMID: 26543747; PubMed Central PMCID: PMC4628133. 16: Lemieux P, Grégoire JP, Thibeault R, Bergeron L. Higher risk of neutropenia associated with piperacillin-tazobactam compared with ticarcillin-clavulanate in children. Clin Infect Dis. 2015 Jan 15;60(2):203-7. doi: 10.1093/cid/ciu780. Epub 2014 Oct 9. PubMed PMID: 25301207. 17: Cielecka-Piontek J, Szymanowska-Powałowska D, Paczkowska M, Łysakowski P, Zalewski P, Garbacki P. Stability, compatibility and microbiological activity studies of meropenem-clavulanate potassium. J Antibiot (Tokyo). 2015 Jan;68(1):35-9. doi: 10.1038/ja.2014.92. Epub 2014 Jul 30. PubMed PMID: 25074659. 18: Nguyen HM, Labreche MJ, Graber CJ. Making sense of cephalosporin and amoxicillin/clavulanate susceptibility testing for uropathogens. Clin Infect Dis. 2014 Nov 1;59(9):1349-50. doi: 10.1093/cid/ciu574. Epub 2014 Jul 16. PubMed PMID: 25034428. 19: Iglesias-Martín F, García-Perla-García A, Yañez-Vico R, Aced-Jiménez E, Arjona-Gerveno E, González-Padilla JD, Gutierrez-Pérez JL, Torres-Lagares D. Comparative trial between the use of amoxicillin and amoxicillin clavulanate in the removal of third molars. Med Oral Patol Oral Cir Bucal. 2014 Nov 1;19(6):e612-5. PubMed PMID: 24880449; PubMed Central PMCID: PMC4259379. 20: Jadhav KS, Marathe PA. Evaluation of potassium clavulanate on ethanol consumption and decision making in the model of ethanol dependence in mice. J Pharmacol Pharmacother. 2014 Oct;5(4):250-2. doi: 10.4103/0976-500X.142439. PubMed PMID: 25422566; PubMed Central PMCID: PMC4231555.